Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients

Chikako Terano(Tokyo Metropolitan Children's Medical Center), Masataka Honda(Rikkyo University), Yoshihiro Fujimura(Japanese Red Cross Society, Japan), Yasuhiro Yoshida(Hokkaido University), Shunsuke Shinozuka(National Hospital Organization), Yusuke Okuda(Kitasato University), Hiroshi Hataya(Japanese Society for Dialysis Therapy), Kenji Ishikura(Kitasato University), Ryoko Harada(Tokyo Metropolitan Children's Medical Center), Sunao Iyoda, Riku Hamada, Wataru Kubota(Tokyo Metropolitan Children's Medical Center), Yuko Hamasaki(Toho University)
Nephrology
April 7, 2017
10.1111/nep.13054
Cited by 7

Related Papers

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial
|The Lancet|2014|450
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|278
Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease
|Clinical and Experimental Nephrology|2013|267
Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies
|Pediatric Nephrology|2021|149
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment
|Kidney International|2014|135